S_nary Previous studies have shown that multidrug resistance (MDR) in the doxorubicin-selected lung tumour cel lines COR-L23/R, GLC4 'ADR and MOR/R is associated with overexpression of the MRP gene.
Acquisition of multidrug resistance (MDR) in vitro is often associated with overexpression of P-glycoprotein (P-gp), the product of the MDR] gene. P-gp functions as an efflux pump for cytotoxic drugs, such as anthracyclines and vinca alkaloids, reducing their cytoplasmic concentration and, hence, toxicity (Gottesman and Pastan, 1993) . We and other groups have characterised cell lines which show the MDR phenotype, e.g. broad cross-resistance spectrum and a decreased drug accumulation, but do not overexpress P-gp (Zijlstra et al., 1987; Slovak et al., 1988; McGrath et al., 1989; Kuiper et al., 1990; Coley et al., 1991) . Therefore, this type of MDR is called non-P-gp MDR. As in P-gp-mediated MDR cells, the drug accumulation deficit is caused by an enhanced drug efflux, which is energy dependent (Coley et al., 1991; Versantvoort et al., 1992) . Recently, a multidrug resistance-associated protein (MRP) gene was cloned from the non-P-gp MDR H69/AR cells (Cole et al., 1992) . The homology of the MRP gene to the ABC superfamily of active transporters (Cole et al., 1992) and the overexpression of MRP found in many non-P-gp MDR cell lines (Krishnamachary and Center, 1993; Slovak et al., 1993; Zaman et al., 1993; Barrand et al., 1994) strongly suggest that MRP is the drug transporter, which was functionally shown to be present, in these cell lines. Indeed, transfection studies with the MRP gene have now demonstrated induction of MDR in sensitive cells, and the transfected cells show a decreased drug accumulation owing to an enhanced drug efflux (Grant et al., 1994; Zaman et al., 1994) .
P-gp-mediated MDR can be reversed by resistancemodifying agents such as verapamil, cyclosporin A and PSC-833. These agents have now entered clinical trials in an attempt to overcome clinical drug resistance. However, these resistance modifiers are usually less effective in reversal of MRP-mediated MDR (Zijlstra et al., 1987; Barrand et al., 1993 ). In the search for more effective and more specific resistance-modifying agents for non-P-gp MDR, we have previously reported that the isoflavonoid genistein increases daunorubicin (DNR) accumulation in several non-P-gp but not in P-gp MDR cell lines (Versantvoort et al., 1993) . Although the toxicity of genistein limits its use as a resistance modifier, it can be used to discriminate between P-gp-and MRP-mediated DNR accumulation deficits.
Most of the well-characterised non-P-gp MDR cells have been selected for resistance to doxorubicin (Twentyman et al., 1986; Zijlstra et al., 1987; Slovak et al., 1988; Kuiper et al., 1990) . Selection in doxorubicin may induce a variety of resistance mechanisms, including a decreased drug accumulation caused by overexpression of P-gp or MRP, a reduced DNA topoisomerase II activity and a more effective detoxification of doxorubicin and/or doxorubicin-induced radicals by glutathione (GSH) (Gottesman and Pastan, 1993; Tew, 1994) . Several reports have demonstrated that elevated levels of GSH, together with increased activities of glutathione S-transferase (GST) or peroxidase, may protect cells from cytotoxic drugs such as melphalan, platinum compounds and anthracyclines (reviewed in Tew, 1994) . Potentiation of the cytotoxicity of doxorubicin has been reported in several P-gp MDR tumour cell lines (Kramer et al., 1988; Dusre et al., 1989) following GSH depletion by exposure to buthionine sulphoximine (BSO), a potent inhibitor of GSH synthesis. The decreased accumulation of doxorubicin was not affected by BSO, but an increase in formation of radicals was measured in GSH-depleted, P-gp-MDR MCF7/ADR cells, indicating that an increased detoxification by GSH/ GST system caused part of the resistance to doxorubicin (Dusre et al., 1989) .
In early studies on MDR not mediated by P-gp, BSO was found to increase doxorubicin/daunorubicin (DNR) toxicity in several non-P-gp MDR cell lines (Lutzky et al., 1989; Larsson et al., 1991; Meijer et al., 1991) . Since GSH and GST levels were 2-fold increased in the MDR GLC4/ADR cells compared with the parental cells, it was suggested that detoxification or doxorubicin by GSH/GST system was an important factor contributing to doxorubicin resistance in this non-P-gp MDR cell line (Meijer et al., 1991) . In the non-P-gp MDR HL60/AR cells, GSH and GST levels were decrased compared with the parental cells, but potentiation of DNR toxicity was accompaned by an increase in cellular DNR accumulation (Lutzky et al., 1989) . In contrast, in the non-P-gp MDR H69/AR cells the toxicity of doxorubicin was not potentiated by BSO (Cole et al., 1990) . In that study, however, only 1 9M BSO was used because of the sensitivity of the resistant cells to BSO, whereas Krishnamachary and Center, 1993; Zaman et al., 1993) . Thus, BSO is able to reverse resistance to anthracyclines in some P-gp-and MRPmediated MDR cells; however, little is known about its mechanism and whether BSO could reverse esistance of other cytotoxic agents involved in the MDR phenotype.
In the present study, we have investigated whether BSO is a resistance modifier for MRP-mediated MDR. Therefore, effects of BSO on the cytotoxicity of DNR, vincristine (VCR) and rhodamine 123 (RhI23) were studied in three MRPoverexpressing, MDR human lung tumour cell lines, COR-L23/R, GLC4/ADR and MOR/R. In order to develop further insght into the mechanism, the effects of BSO on DNR and Rhl23 transport were examined, and these were related to changes in cellular GSH levels. al., 1986; Barrand et al., 1993) , the small-ell lung carcinoma cell ie GLC4 and the MDR subie GLC4/ADR (Zijlstra et al., 1987; Meijer et al., 1991) al., 1986; Zijlstra et al., 1987; Versantvoort et al., 1992) but each overexpres the MRP gene (Zaman et al., 1993; Barrand et al., 1994) . Furthermore, a P-gp overxCpressing small-cell lung carcinoma cell ine, H69/LX4, and its parental cell line, H69/P, were used (Twentyman et al., 1986 In order to establish cellular steady-state accumulation of RhI23, 0.1-0.3 x 10' cells were plated in six-well plates (Falcon) and cultured for 2 days. Tben, cells were exposed for 20 h to 0.01 pg ml-' Rhl23, harvested and the accumulation of Rh123 was measured by flow cytometry. To determine the effect of BSO on Rhl23 steady-state accumulation, BSO was added 4 h before the addition of Rhl23 (i.e. incubation with BSO for a total of 24 h).
Glutathione content Proteins from 0.3-1.5 x 10' cells were precipitated with 2% trichloroacetic acid (TCA). The cellular GSH content of the supernatant was determined with FlInan's reagent, 5,5-dithiobis(2-nitrobenzoic acid), and absorbance was measured at 412 nm (Sedlak and Lindsay, 1968) .
Efflunx of GSH from the cells was measured as described by Sze et al. (1993) . Cells were resuspended (5-l0 x 10' cells ml-') in 140 mM sodium chloride, 5 mM potassium chloride, 1 mM magnesium chloride, 1 mM calcium chloride, 8 mM disodium hydrogen phosphate, 1.5 mM potassium dihydrogen phosphate, 1 mg ml-' D-glucose and 4 mM Lglutamine and buffered with 20mM Hepes (pH 7.3). Cells were incubated at 3TC in presnce of 0.2 mM acivic'n, an inhibitor of T-glutyltransptidase, centrifuged and aliquots of the supernatant were analysed for thiol content. (1994) . Membrane proteins were isolated from a post-nuclei homogenate by centrifugation at 25000 g for 15min at 4C. This 25000 g fraction contained more than 90% of MRP (Versantvoort et al., 1995 Fugwe expments.
I increase in steady-state accumulation of DNR and Rh 123 was measured in the parental MOR/P and COR-L23/P cells. However, no effect of BSO was measured in the GLC4 and H69/P cells. In contrast to the MRP MDR cell lines, BSO had no effect on the decreased DNR accumulation in P-gp MDR cell line H69/LX4. Figure 2 shows that the BSO-induced increase in DNR and Rhl23 accumulation in the COR-L23/R cells was caused by inhibition of the enhanced drug efflux. BSO did not affect the efflux of DNR and Rh123 in the parental COR-L23/P cells. Inhibition of the enhanced drug efflux was also observed in the other MRP MDR cell lines (data not shown).
Intracellular glutathione levels
Since BSO is an inhibitor of glutathione synthesis and might affect drug transport via this pathway, we determined the effects of BSO treatment on cellular GSH content (Table III) . Basal GSH levels did not correlate with resistance: the COR-L23/R cells had a lower, the GLC4/ADR cells a higher and the MOR/R cells a similar GSH content compared with their parental cell lines. These results are in agreement with reported data for these cell lines (Meijer et al., 1991; Rhodes GH ad (Table III) (Table IV) . In contrast to GSH itself, monoesters of GSH are well transported into cells and hydrolysed intracellularly to GSH (Meister, 1988) . Monoesters of GSH have, therefore, been shown effective in increasng intracellular GSH levels even in the presence of BSO (Meister, 1988) . As is shown in Table IV 66±12 (3) 213± 6 (2) 158±21 (2) 331±48 (3) 260±52 (3)3 GLC4 111 10 (2) 124±8 (2) 126± 7 (2) 130±9 (2) GLC4/ADR 12±4 (4) 11±5 (4) 31±4 (2) 14±1 (2) 90±26 (4) 54±17 (4) Cells were incubated with 0, 2. (Table V) . If the transport of DNR were to interact with the transport of GSH, the effects would be maximal under conditions in which the active DNR transport is saturated. Previously, we have shown in the GLC4/ADR cells that the transport of DNR became saturated at concentrations (in the medium) higher than 5 JIM and was almost completely saturated at 25 JLM (Versantvoort et al., 1994) . However, 25 jiM DNR had no effect on GSH release in any of the cell lines (Table V) .
MRP RNA and protein expression It has been reported that oxidative stress, for example caused by cellular GSH depletion, increases expression of heat shock proteins, GSTs and other xenobiotic-metabolising enzymes (Bergelson et al., 1994; Sierra-Rivera et al., 1994 Figure 5 ) and that restoration of cellular GSH levels in BSO-treated MRP-overexpressing cells reinduces the accumulation deficit of DNR (Table IV) . In contrast to these effects on MRP MDR cell lines, cellular GSH depletion had no effect on the decreased DNR accumulation in the P-gp MDR H69/LX4 cell line (Table II) . Thus, these data indicate that drug transport is regulated differently in MRP-and P-gp-overexpressing cells. Transfection of the MRP gene in drug-sensitive cells has now been shown to confer MDR associated with a decreased accumulatior of drugs (Grant et al., 1994; Zaman et al., 1994) . It is therefore likely that MRP is the drug transporter which has been shown functionally present in many non-Pgp-MDR cells (Slovak et al., 1988; McGrath et al., 1989; Kuiper et al., 1990; Coley et al., 1991) . The pharmacological properties of drug transport in MRP-and P-gp-overexpressing cell lines show very similar characteristics (Broxterman and Versantvoort, 1995) . Most of the drugs that are transported by P-gp (for example doxorubicin, DNR, VCR, VP-16 and Rhl23), have now been reported to be transported in MRP-overexpressing cell lines (Slovak et al., 1988; Versantvoort et al., 1992 Versantvoort et al., . 1993 Twentyman et al., 1994) . The accumulation of drugs is decreased due to an enhanced, energy-dependent efflux from the cells, and we have demonstrated that the transport of DNR in the MRP-overexpressing GLC4/ADR cells is saturable (Versantvoort et al., 1994) with an apparent K,, of 1.4 gM which is similar to the K,,, of DNR transport found in P-gp MDR cell lines (Spoelstra et al., 1992) . Nevertheless, there are important differences between MRP and P-gp in the modulation of the drug transport by resistance modifiers. Cyclosporin A and PSC-833, effective resistance-modifying agents for P-gp-mediated MDR, were shown to be less potent in reversing resistance in the COR-L23 R cells (Barrand et al., 1993) . In addition, Zaman et al. (1994) reported that cyclosponrn A could not reverse the DNR accumulation deficit in the MRPtransfected cells. In contrast, we have shown that the isoflavonoid genistein increases DNR accumulation in several non-P-gp MDR cells but not in P-gp MDR cells (Versantvoort et al., 1993) . It was shown in the GLC4/ADR cells that gemstein inhibited the DNR transport by competition with DNR (Versantvoort et al., 1994) (Versantvoort et al., 1994) .
In the second model, the cytotoxic drugs would be transported not by MRP but by a latent drug transport protein present in the cells. MRP might form a membrane-bound complex with the drug transport protein. The transport of glutathione S-conjugates would then allow the transport of drugs through a series of conformational changes. As in the above described model, inhibition of the glutathione Sconjugate transport would inhibit the drug transport, but drug transport could also be inhibited at its drug binding sites.
In conclusion, our results indicate that transport of drugs in MRP-overexpressing but not in P-gp-overexpressing MDR cells can be regulated by cellular GSH levels. In the models described above we have assumed that GSH depletion inhibited the drug transport through inhibition of the transport of glutathione S-conjugates by MRP. However, the possibility that GSH depletion causes a conformational chang in MRP, which inhibits the transport of drugs, or activates an inhibitory molecule cannot be excluded. In this case MRP-mediated glutathione S-conjugate and drug transport can be completely distinct and separable. Further inhibition studies as well as studies on transport of cytotoxic agents in insde-out plasma membrane vesicles of MRPoverpresing cells will provide evidence in which form the cytotoxic agents are transported and their dependence on GSH and/or glutathione S-conjugates. 
